Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ACRS

ACRS - Aclaris Therapeutics Inc Stock Price, Fair Value and News

$3.52-0.35 (-9.04%)
Market Closed

12/100

ACRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

ACRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.6

Target 3M

$4.05

Target 6M

$3.82

ACRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACRS Price Action

Last 7 days

-20.4%

Last 30 days

16.9%

Last 90 days

41.4%

Trailing 12 Months

47.3%

ACRS RSI Chart

ACRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ACRS Valuation

Market Cap

381.4M

Price/Earnings (Trailing)

-2.69

Price/Sales (Trailing)

24.23

EV/EBITDA

-1.76

Price/Free Cashflow

-8.87

ACRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.6

Target 3M

$4.05

Target 6M

$3.82

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

15.7M

Rev. Growth (Yr)

-24.09%

Rev. Growth (Qtr)

85.65%

ACRS Earnings

Earnings (TTM)

-141.7M

Earnings Growth (Yr)

-92.64%

Earnings Growth (Qtr)

5.28%

ACRS Profitability

Operating Margin

85.62%

EBT Margin

-838.96%

Return on Equity

-117.97%

Return on Assets

-80.71%

Free Cashflow Yield

-11.28%

ACRS Investor Care

Shares Dilution (1Y)

51.68%

Diluted EPS (TTM)

-1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202517.8M16.8M15.7M0
202431.1M32.0M27.1M18.7M
202330.8M31.2M21.4M31.2M
20226.4M6.1M23.5M29.8M
20216.9M6.6M6.8M6.8M
20204.4M5.5M6.0M6.5M
20199.7M6.9M6.8M4.2M
20182.9M6.5M6.9M9.6M
201700941.5K1.8M
201525.0K51.3K77.7K104.0K
201419.3K017.7K16.0K
201300021.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aclaris Therapeutics Inc

ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
 CEO
 WEBSITEaclaristx.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES100

Aclaris Therapeutics Inc Frequently Asked Questions

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Aclaris Therapeutics Inc is 381.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ACRS's fair value in chart for subscribers.

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

As of Wed Jan 28 2026, ACRS's PE ratio (Price to Earnings) is -2.69 and Price to Sales (PS) ratio is 24.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Aclaris Therapeutics Inc has provided -0.168 (multiply by 100 for percentage) rate of return.